Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of (Early) Combination Salvage Therapy With Venetoclax and Intensified Decitabine in Relapsed/Refractory AML

NCT06156579 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT06156579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06156579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of (Early) Combination Salvage Therapy With Venetoclax and Intensified Decitabine in Relapsed/Refractory AML
Lead sponsor
University Hospital Tuebingen
Phase
Phase 2
Overall status
Recruiting
Start date
November 4, 2023
Completion date
March 31, 2027
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml, mds